Author Affiliations1Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2; State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130
2Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2
3State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130
4Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2
5State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130
6Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2
7Institute of Internal Medicine SB RAMS 630089, Novosibirsk , Boris Bogatkov str., 175/1
8Joint Stock Company «VECTOR-BEST» 630117, VECTOR-BEST PO BOX 492, Novosibirsk-117
1. Antonov V.G., Kozlov V.K. The pathogenesis of oncological diseases: immune and biochemical phenomena and mechanisms. Extracellular and cellular mechanisms of general immunosupression and immune resistance // Cytokines and inflammation. 2004. 3. (1). 8-19. (in Russian)
2. Vladimirskaya E.B. Mechanisms of hematopoiesis and leukemogenesis. Moskow, 2007. 150 p. (in Russian)
3. Zhevak T.N., Chesnokova N.P., Shelekhova T.V. Regularities of changes of cytokine status in chronic lymphocytic leukemia and their role in the pathogenesis of progressive forms of the disease // Saratovskiy nauchno-meditsinskiy zhurnal. 2012. 8. (2). 203–209.(in Russian)
4. Zaporozhan V.N. Molecular genetics in clinical medicine: achievements and prospects // Zhurnal Akademii meditsinskikh nauk Ukraini. 2003. 9. (4). 638–648. (in Russian)
5. Kozlov V.A., Borisov A.G., Smirnova S.V., Savchenko A.A. Practical aspects of diagnostics and treatment of immune disorders. Novosibirsk, 2009. 274 p. (in Russian)
6. Perevodchikova N.I. Guidelines for chemotherapy of tumors. Moscow, 2011. 512 p. (in Russian)
7. Ryzhikova S.L., Druzhinina Yu.G., Ryabicheva T.G., Varaksin N.A. Standartization of methods for determining of cytokine production by blood cells ex vivo // Clinicheskaya laboratornaya diagnostika. 2011. (11). 49–53. (in Russian)
8. Ryabicheva T.G., Varaksin N.A., Timofeeva N.V. et al. Tests of immunomodulators in the system ex vivo // Novosti «Vector-Best». 2006. 4. (42). 12–14. (in Russian)
9. Serebryanaya N.B., Novik A.A., Voloshin S.V., Novitskiy A.V. The clinical significance of some cytokines in malignant non-Hodgkin's lymphoma // Tsytokiny i vospaleniye. 2002. 1. (3). 21–26. (in Russian)
10. Airoldi I., Raffaghello L., Cocco C. Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes // Clin. Cancer Res. 2004. 10. (1, Pt. 1). 144-154.
11. Alexandrakis M.G., Passam F.H., Sfiridaki K. et al. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival // Leuk. Res. 2004. 28. (3). 259-266.
12. Campbell J.D., Cook G., Robertson S.E. et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15 // J. Immunol. 2001. 167. 553–561.
13. Chauhan D., Hideshima T., Anderson K. Cytokines in multiple myeloma. Therapeutic implications // Cytokines in the Genesis and Treatment of Cancer. Part II. Totowa: Humana Press Inc., 2007. 181–197.
14. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival // Cancer. 1975. 36. (3). 842–854.
15. Franchimont D. Overview of the actions of glucocorticoids on the immune response: A good model to characterize new pathways of immunosuppression for new treatment strategies // Ann. N. Y. Acad. Sci. 2004. 1024. 124–137.
16. Goto N., Tsurumi H., Kasahara S. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens // Eur. J. Haematol. 2011. 87. (3). 217-227.
17. Kaiser R., Dubovy P., Haninec P. Vascular endothelial growth factor // Cesk. Fisiol. 2011. 60. (2). 48-51.
18. Kaspar M., Trachsel E., Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis // Cancer Res. 2007. 67. (10). 4940-4948.
19. Kline M., Donovan K., Welik L. et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression // Leuk. Res. 2007. 31. (5). 591–598.
20. Kuku I., Bayraktar M.R., Kaya E. et al. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma // Mediat. Inflam. 2005. 3. 171–174.
21. Penafuerte C., Bautista-Lopez N., Boulassei MR. et al. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation // Cancer Res. 2010. 70. (14). 6106.
